Abstract: A closed-loop control for a medical therapeutic system is disclosed that includes one or more processes or components for/in the medical therapeutic system, a controller configured to determine whether one or more operations of the process(es) or component(s) are within a corresponding safety envelope, and one or more sensors. The process(es)/component(s) are configured to deliver a controlled amount of a substance, energy or force to a patient. The sensor(s) are configured to measure or determine a value of a measurable parameter of the process(es)/component(s) and/or effected by the operation(s), and provide the value(s) of the measurable parameter(s) to the controller. The controller determines whether each of the operation(s) are within the corresponding safety envelope according to a corresponding function that mathematically describes the operation. The safety envelope corresponds to known safe values of the measurable parameter, or an unmeasured parameter based on the measurable parameter.

Abstract: Systems and methods described herein can relate to a web browser-based application programming interface (API) that can control the authorization of data transmissions within a networked environment. The system enables content items displayed in a web page to make a call to the browser to request that the browser register the content item with the browser. The web browser can control the network transmissions to content items approved or authorized by the web browser. The system can reduce the number of transmissions that do not result in content for the client device—saving bandwidth and computational resources for the client device.

Abstract: A closed-loop control for a medical therapeutic system is disclosed that includes one or more processes or components for/in the medical therapeutic system, a controller configured to determine whether one or more operations of the process(es) or component(s) are within a corresponding safety envelope, and one or more sensors. The process(es)/component(s) are configured to deliver a controlled amount of a substance, energy or force to a patient. The sensor(s) are configured to measure or determine a value of a measurable parameter of the process(es)/component(s) and/or effected by the operation(s), and provide the value(s) of the measurable parameter(s) to the controller. The controller determines whether each of the operation(s) are within the corresponding safety envelope according to a corresponding function that mathematically describes the operation. The safety envelope corresponds to known safe values of the measurable parameter, or an unmeasured parameter based on the measurable parameter.

Abstract: The present disclosure provides systems and methods for content quasi-personalization or anonymized content retrieval via aggregated browsing history of a large plurality of devices, such as millions or billions of devices. A sparse matrix may be constructed from the aggregated browsing history, and dimensionally reduced, reducing entropy and providing anonymity for individual devices. Relevant content may be selected via quasi-personalized clusters representing similar browsing histories, without exposing individual device details to content providers.

Abstract: The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has ?-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

Abstract: Systems and methods described herein can relate to a web browser-based application programming interface (API) that can control the authorization of data transmissions within a networked environment. The system enables content items displayed in a web page to make a call to the browser to request that the browser register the content item with the browser. The web browser can control the network transmissions to content items approved or authorized by the web browser. The system can reduce the number of transmissions that do not result in content for the client device—saving bandwidth and computational resources for the client device.

Abstract: A closed-loop control for a medical therapeutic system is disclosed that includes one or more processes or components for/in the medical therapeutic system, a controller configured to determine whether one or more operations of the process(es) or component(s) are within a corresponding safety envelope, and one or more sensors. The process(es)/component(s) are configured to deliver a controlled amount of a substance, energy or force to a patient. The sensor(s) are configured to measure or determine a value of a measurable parameter of the process(es)/component(s) and/or effected by the operation(s), and provide the value(s) of the measurable parameter(s) to the controller. The controller determines whether each of the operation(s) are within the corresponding safety envelope according to a corresponding function that mathematically describes the operation. The safety envelope corresponds to known safe values of the measurable parameter, or an unmeasured parameter based on the measurable parameter.

Abstract: Systems and methods described herein can relate to a web browser-based application programming interface (API) that can control the authorization of data transmissions within a networked environment. The system enables content items displayed in a web page to make a call to the browser to request that the browser register the content item with the browser. The web browser can control the network transmissions to content items approved or authorized by the web browser. The system can reduce the number of transmissions that do not result in content for the client device—saving bandwidth and computational resources for the client device.

Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

Abstract: An air gun includes a gun barrel through which a bore passes from a breech end to a muzzle end, a piston, and a spring housed within a main housing. The spring biases the piston forward towards the gun barrel. An air compression chamber is defined by a cylindrical interior surface and a forward face of the piston. A cocking mechanism enables a user to forcibly retract the piston rearward from the gun barrel against the spring bias to a cocked position. The main housing includes a rearward cavity that accepts the rearward retraction of at least a portion of the piston, which portion may include a coating of paint. A first viewing port into the rearward cavity may have a translucent cover and visually indicates a state of rearward retraction of the piston.

Abstract: A closed-loop control for a medical therapeutic system is disclosed that includes one or more processes or components for/in the medical therapeutic system, a controller configured to determine whether one or more operations of the process(es) or component(s) are within a corresponding safety envelope, and one or more sensors. The process(es)/component(s) are configured to deliver a controlled amount of a substance, energy or force to a patient. The sensor(s) are configured to measure or determine a value of a measurable parameter of the process(es)/component(s) and/or effected by the operation(s), and provide the value(s) of the measurable parameter(s) to the controller. The controller determines whether each of the operation(s) are within the corresponding safety envelope according to a corresponding function that mathematically describes the operation. The safety envelope corresponds to known safe values of the measurable parameter, or an unmeasured parameter based on the measurable parameter.

Abstract: Systems and methods described herein can relate to a web browser-based application programming interface (API) that can control the authorization of data transmissions within a networked environment. The system enables content items displayed in a web page to make a call to the browser to request that the browser register the content item with the browser. The web browser can control the network transmissions to content items approved or authorized by the web browser. The system can reduce the number of transmissions that do not result in content for the client device—saving bandwidth and computational resources for the client device.

Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

Abstract: Carbon nanotubes (CNTs), graphene platelets, or other forms of graphene are incorporated into raw materials before products and product components are manufactured from the materials. For example, CNTs may be incorporated into metallic powders, which can be pressed and sintered into metallic products and product components. CNTs or graphene platelets can also be incorporated into plastics, ceramics, metals, or other materials used to construct products and product components by additive manufacturing. When incorporated into the products and product components, the CNTs or graphene platelets can improve various properties of the products and product components, such as thermal conductivity, electrical conductivity, or structural properties.

Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type I diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

Abstract: The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.